Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 25, Issue 5, 2012, Pages 297-305

  Chan, John Gar Yan ^a   Traini, Daniela ^a   Chan, Hak Kim ^a   Young, Paul M ^a   Kwok, Philip Chi Lip ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cystic fibrosis; Inhaled therapy; Mucociliary clearance; Nebulizer

Indexed keywords

MANNITOL; POLYOL; SODIUM CHLORIDE; SORBITOL; XYLITOL;

AEROSOL; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SOLUBILITY; FEASIBILITY STUDY; GRAVIMETRY; LASER DIFFRACTION; MEDICAL NEBULIZER; MOLECULAR WEIGHT; MUCOCILIARY CLEARANCE; OSMOLARITY; PARTICLE SIZE; SOLUBILITY; VIBRATING MESH NEBULIZER; VISCOSITY;

ADMINISTRATION, INHALATION; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEASIBILITY STUDIES; MANNITOL; MUCOCILIARY CLEARANCE; NEBULIZERS AND VAPORIZERS; SODIUM CHLORIDE; SOLUBILITY; SORBITOL; TIME FACTORS; VIBRATION; VISCOSITY; XYLITOL;

EID: 84867064558     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0961     Document Type: Article

References (41)

1. Bilton D, Robinson P, Cooper P, Gallagher C, Kolbe J, and Charlton B: Phase III study of inhaled dry powder mannitol ("Bronchitol") in cystic fibrosis results from the 6 month open label phase. Am J Respir Crit Care Med. 2010; 181:A2338.
2. Daviskas E, Anderson SD, Eberl S, and Young IH: Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction. Respir Med. 2010;104:1645-1653.
3. Daviskas E, Anderson SD, Jaques A, and Charlton B: Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest. 2010;137: 861-868.
4. Heijerman H, Westerman E, Conway S, and Touw D: Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cystic Fibros. 2009;8:295-315.
5. Thelin WR, and Boucher RC: The epithelium as a target for therapy in cystic fibrosis. Curr Opin Pharmacol. 2007;7: 290-295.
6. Minasian C, Wallis C, Metcalfe C, and Bush A: Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax. 2010;65:51-56.
7. Bye PTP, and Elkins MR: Other mucoactive agents for cystic fibrosis. Paediatr Respir Rev. 2007;8:30-39.
8. Zabner J, Seiler MP, Launspach JL, Karp PH, Kearney WR, Look DC, Smith JJ, and Welsh MJ: The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. Proc Natl Acad Sci USA. 2000;97:11614-11619.
9. Goralski JL, Boucher RC, and Button B: Osmolytes and ion transport modulators: new strategies for airway surface rehydration. Curr Opin Pharmacol. 2010;10:294-299.
10. Chan JGY, Kwok PCL, Young PM, Chan H-K, and Traini D: Mannitol delivered by vibrating mesh nebulisation for enhancing mucociliary clearance. J Pharmaceut Sci. 2011;100: 2693-2702.
11. Hess DR: Aerosol delivery devices in the treatment of asthma. Respir Care. 2008;53:699-725.
12. Lass JS, Sant A, and Knoch M: New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin Drug Deliv. 2006;3:693-702.
13. Waldrep JC, and Dhand R: Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv. 2008;5:114-119.
14. Bensouissi A, Roge B, and Mathlouthi M: Effect of conformation and water interactions of sucrose, maltitol, mannitol and xylitol on their metastable zone width and ease of nucleation. Food Chem. 2010;122:443-446.
15. Sajjan U, Moreira J, Liu M, Humar A, Chaparro C, Forstner J, and Keshavjee S: A novel model to study bacterial adherence to the transplanted airway: inhibition of Burkholderia cepacia adherence to human airway by dextran and xylitol. J Heart Lung Transplant. 2004;23:1382-1391.
16. Durairaj L, Launspach J, Watt JL, Mohamad Z, Kline J, and Zabner J: Safety assessment of inhaled xylitol in subjects with cystic fibrosis. J Cystic Fibros. 2007;6:31-34.
17. Zabner J, Durairaj L, and Launspach J: Clinical trial: aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects. Uo Iowa, trans. National Clinical Trial ID: NCT00928135, 2011.
18. Durairaj L, Launspach J, Watt JL, Businga TR, Kline JN, Thorne PS, and Zabner J: Safety assessment of inhaled xylitol in mice and healthy volunteers. Respir Res. 2004;5:13.
19. Rytting E, Lentz KA, Chen XQ, Qian F, and Vakatesh S: Aqueous and cosolvent solubility data for drug-like organic compounds. AAPS J. 2005;7:E78-E105.
20. Iborra JL, Obon JM, Manjon A, and Canovas M: Water concentration and activity effects on aminocylase in aqueous/organic one-liquid-phase systems. Biocatalyst. 1992;7:37-48.
21. Hoekman JD, and Ho RJ: Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution. AAPS PharmSciTech. 2011;12:534-543.
22. Clark AR: The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharmaceut. 1995;115:69-78.
23. de Boer AH, Gjaltema D, Hagedoorn P, and Frijlink HW: Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int J Pharmaceut. 2002;249:219-231.
24. Keller M, Tservistas M, Bucholski A, Hug M, and Knoch M: Correlation of laser diffraction and cascade impaction data for aqueous solutions aerosolized by the eFlow® electronic nebulizer (poster). In: Respiratory Drug Delivery. Vol X: Boca Raton, FL; pp. 745-748, 2006.
25. Mitchell JP, and Tservistas M: Laser diffractometry and cascade impaction for nebulizer product characterization. Pharmeur Sci Notes. 2006;2006:49-52.
26. Vecellio L, Grimbert D, Becquemin MH, Boissinot E, Le Pape A, Lemarié E, and Diot P: Validation of laser diffraction method as a substitute for cascade impaction in the european project for a nebulizer standard. J Aerosol Med. 2001; 14:107-114.
27. Ziegler J, and Wachtel H: Comparison of cascade impaction and laser diffraction for particle size distribution measurements. J Aerosol Med. 2005;18:311-324.
28. Rao N, Kadrichu N, and Ament B: Application of a droplet evaporation model to aerodynamic size measurement of drug aerosols generated by a vibrating mesh nebulizer. J Aerosol Med Pulmon Drug Deliv. 2010;23:295-302.
29. CEN-Nebulizer Standard EN 13544-1. Respiratory Therapy Equipment - Part 1: Nebulizing Systems and Their Components. Annex DD Method for Characterization of Nebulizers with Respect to Droplet Size Using Laser Diffraction; 2001.
30. Dumouchel C, Yongyingsakthavorn P, and Cousin J: Light multiple scattering correction of laser-diffraction spray dropsize distribution measurements. Int J Multiphase Flow. 2009; 35:277-287.
31. Martin AR, Gleske J, Katz IM, Hartmann M, Mullinger B, Haussermann S, Caillibotte G, and Scheuch G: Laser diffraction characterization of droplet size distributions produced by vibrating mesh nebulization in air and a helium-oxygen mixture. J Aerosol Sci. 2010;41:1159-1166.
32. Berg E, Svensson JO, and Asking L: Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J Aerosol Med. 2007;20:97-104.
33. Kwok PCL, Trietsch SJ, Kumon M, and Chan H-K: Electrostatic charge characteristics of jet nebulized aerosols. J Aerosol Med Pulmonary Drug Deliv. 2010;23:149-159.
34. Elhissi AMA, Karnam KK, Danesh-Azari MR, Gill HS, and Taylor KMG: Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers. J Pharm Pharmacol. 2006;58:887-894.
35. Deshpande D, Blanchard J, Srinivasan S, Fairbanks D, Fujimoto J, Sawa T, Wiener-Kronish J, Schreier H, and Gonda I: Aerosolization of lipoplexes using AERx® pulmonary delivery system. AAPS J. 2002;4:12-21.
36. Rosell J, Schuster J, Gonda I, and Liu K: Electrostatic charge in AERX™ aerosols. J Aerosol Med. 2001;14:405.
37. Zhang G, David A, and Wiedmann TS: Performance of the vibrating membrane aerosol generation device: Aeroneb Micropump Nebulizer. J Aerosol Med. 2007;20: 408-416.
38. Ghazanfari T, Elhissi AM, Ding Z, and Taylor KM: The influence of fluid physicochemical properties on vibratingmesh nebulization. Int J Pharm. 2007;339:103-111.
39. Zhu C, Ma Y, and Zhou C: Densities and viscosities of sugar alcohol aqueous solutions. J Chem Eng Data. 2010;55:3882-3885.
40. Vecellio L: The Mesh Nebuliser: a recent technical innovation for aerosol delivery. Breathe. 2006;2:253-260.
41. Durairaj L, Neelakantan S, Launspach J, Watt JL, Allaman MM, Kearney WR, Veng-Pedersen P, and Zabner J: Bronchoscopic assessment of airway retention time of aerosolized xylitol. Respir Res. 2006;7:27.